National Bank of Canada FI Has $265,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

National Bank of Canada FI lowered its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 94.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,983 shares of the life sciences company's stock after selling 32,114 shares during the period. National Bank of Canada FI's holdings in Illumina were worth $265,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ILMN. Golden State Wealth Management LLC acquired a new stake in shares of Illumina during the fourth quarter worth approximately $32,000. Versant Capital Management Inc raised its stake in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina during the 4th quarter valued at about $45,000. Assetmark Inc. lifted its holdings in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after buying an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Illumina in the 4th quarter valued at approximately $48,000. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. Barclays lowered their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research report on Thursday, April 10th. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Guggenheim decreased their price target on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Canaccord Genuity Group dropped their price target on shares of Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $138.70.

Remove Ads

Illumina Price Performance

NASDAQ ILMN traded down $1.06 during trading hours on Wednesday, reaching $73.53. 195,616 shares of the company's stock were exchanged, compared to its average volume of 2,260,490. The firm has a fifty day moving average of $86.63 and a 200-day moving average of $121.54. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock has a market cap of $11.65 billion, a PE ratio of -9.58, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.